Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Sep 19, 2016	CT ORDER	CT ORDER	View HTML 9999999997-16-025877.pdf
Jan 09, 2017	CT ORDER	CT ORDER	View HTML 9999999997-17-000052.pdf
Sep 12, 2017	CT ORDER	CT ORDER	View HTML 9999999997-17-008525.pdf
Sep 04, 2018	CT ORDER	CT ORDER	View HTML 9999999997-18-007614.pdf
Mar 18, 2019	CT ORDER	CT ORDER	View HTML 9999999997-19-001396.pdf 9999999997-19-001396.rtf
Sep 27, 2019	CT ORDER	CT ORDER	View HTML 9999999997-19-007138.pdf 9999999997-19-007138.rtf
Mar 16, 2020	CT ORDER	CT ORDER	View HTML
Jul 01, 2021	CT ORDER	CT ORDER	View HTML 9999999997-21-003887.pdf
Feb 19, 2015	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	View HTML 0000912057-15-000045.pdf 0000912057-15-000045.rtf 0000912057-15-000045.xls
Apr 29, 2015	EFFECT	EFFECT	View HTML 9999999995-15-001054.pdf 9999999995-15-001054.rtf 9999999995-15-001054.xls

Investors & Media

Transformative science, targeted medicines

SEC Filings

SEC Filings

Pagination